Director/PDMR Shareholding

RNS Number : 4585Q
Oxford Biomedica PLC
17 June 2015
 

 

 

 

 

 

 

Oxford BioMedica plc Director's Share Purchase

 

 

Oxford, UK - 17 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 17 June 2015 one of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:

 

 

 

 

 

 

Interest after purchase

Director / PDMR

Title

Price per share (p)

Number of Ordinary Shares acquired

Number of Ordinary Shares

% of total

issued share capital

Andrew Heath

Non-executive director

8.092p

100,000

1,200,000

0.05%

 

The issued share capital of the Group is 2,568,590,171 1p ordinary shares.

 

- Ends -

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

 

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RDSBDGDLGDBBGUR